Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma
- PMID: 12697885
- DOI: 10.1200/JCO.2003.05.191
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma
Abstract
Purpose: To compare the outcomes associated with modifications in three consecutive protocols employed by the Italian Co-Operative Group for Neuroblastoma (ICGNB) in disseminated neuroblastoma.
Patients and methods: Between January 1985 and November 1997, a total of 359 children aged 1 to 15 years with newly diagnosed stage 4 neuroblastoma were enrolled in three consecutive protocols. Compared with ICGNB-85, the ICGNB-89 protocol contained two more chemotherapy cycles, and some drugs were given at greater doses, whereas in the ICGNB-92 protocol, the induction phase included a chelating agent, and individual cycles contained four drugs instead of two.
Results: A total of 330 of 359 evaluable children were included in this analysis; 106 children were treated with ICGNB-85, 65 children were treated with ICGNB-89, and 159 children were treated with ICGNB-92 protocols. Radical resection of primary tumor was carried out in 59.4%, 50.8%, and 57.9% of the patients, respectively. Major tumor response after induction therapy was achieved in 66.7%, 69.2%, and 68.6% of the patients, respectively. A total of 218 of 232 patients received consolidation therapy consisting of conventional chemotherapy in 65 patients and of high-dose chemotherapy in 153 patients. Disease recurrence or progression occurred in 82.1%, 69.2%, and 74.8% of the patients, respectively. Therapy-related deaths occurred in 1.9%, 12.3%, and 6.9% of the patients, respectively. Five-year overall survival (OS) for the three studies was 26%, 23%, and 28%, and event-free survival (EFS) was 19%, 17%, and 17%, respectively.
Conclusion: The therapeutic modifications adopted in the ICGNB-89 and ICGNB-92 protocols were not associated with a significant improvement in response rate or in the 5-year OS and EFS as compared with the ICGNB-85 protocol. Attempts at intensifying chemotherapy were associated with greater toxicity.
Similar articles
-
Neuroblastoma.Saudi Med J. 2001 Aug;22(8):674-80. Saudi Med J. 2001. PMID: 11573111
-
[Evaluation of efficacy of treatment for 30 children with neuroblastoma].Ai Zheng. 2003 Dec;22(12):1343-5. Ai Zheng. 2003. PMID: 14693065 Chinese.
-
Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.J Clin Oncol. 2005 Jan 20;23(3):532-40. doi: 10.1200/JCO.2005.03.054. J Clin Oncol. 2005. PMID: 15659499 Clinical Trial.
-
Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.J Clin Oncol. 1991 Jun;9(6):1050-8. doi: 10.1200/JCO.1991.9.6.1050. J Clin Oncol. 1991. PMID: 2033419 Review.
-
Role of autotransplantation in neuroblastoma.Hematol Oncol Clin North Am. 1993 Jun;7(3):647-62. Hematol Oncol Clin North Am. 1993. PMID: 8344884 Review.
Cited by
-
Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.Onco Targets Ther. 2012;5:21-9. doi: 10.2147/OTT.S14578. Epub 2012 Mar 2. Onco Targets Ther. 2012. PMID: 22419878 Free PMC article.
-
[Neuroblastoma].Clin Transl Oncol. 2005 Apr;7(3):133-45. doi: 10.1007/BF02708748. Clin Transl Oncol. 2005. PMID: 15899223 Review. Spanish. No abstract available.
-
Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.J Clin Oncol. 2011 Jan 10;29(2):208-13. doi: 10.1200/JCO.2010.31.7107. Epub 2010 Nov 29. J Clin Oncol. 2011. PMID: 21115869 Free PMC article. Clinical Trial.
-
Neuroblastic tumors and neurofibromatosis type 1: A retrospective multicenter study in Italy and systematic review of the literature.Front Pediatr. 2022 Nov 4;10:950911. doi: 10.3389/fped.2022.950911. eCollection 2022. Front Pediatr. 2022. PMID: 36405824 Free PMC article.
-
CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.Cell Cycle. 2013 Apr 1;12(7):1091-104. doi: 10.4161/cc.24091. Epub 2013 Mar 5. Cell Cycle. 2013. PMID: 23462184 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical